The WHO's approval of Coartem Baby marks a historic achievement in malaria treatment for newborns and young infants, addressing a critical gap in healthcare. Developed by Novartis and Medicines for Malaria Venture, this innovative drug provides a safer, accurately dosed option, highlighting the importance of inclusive pharmaceutical innovation.

















